Home > Boards > US Listed > Biotechs > Orthovita, Inc. (VITA)

"Orthovita in Conjunction with Canaccord Adams will Conduct

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
alien42 Member Profile
Member Level 
Followed By 98
Posts 15,577
Boards Moderated 2
Alias Born 01/28/01
160x600 placeholder
alien42 Member Level  Tuesday, 06/12/07 08:01:32 AM
Re: None
Post # of 30 
"Orthovita in Conjunction with Canaccord Adams will Conduct an Institutional Investors Meeting on Thursday, June 14th, in Chicago
Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, announced today that it will conduct an institutional investor meeting in conjunction with Canaccord Adams, Inc. on Thursday, June 14th, 2007 in Chicago, IL. Antony Koblish, president and chief executive officer of Orthovita, Albert J. Pavucek, Jr., Chief Financial Officer, and several members of Orthovita’s management team will present at the meeting scheduled from 1:00 p.m. to 5:00 p.m. Central Time, in the Washington Room of The Sears Tower, 233 South Wacker Drive, Chicago, IL. William J. Plovanic, CFA, managing director, equity research from Canaccord Adams will be co-hosting the meeting.

In addition, the meeting will feature guest speaker H. Paul Hatten, Jr., M.D., from Indian River Radiology of Vero Beach, Florida, who will give a presentation entitled “Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at approximately 2:00 p.m. and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of Orthovita’s CORTOSS compared to commercially available PMMA bone cements in osteoporotic compression fractures of the vertebra(e). A total of 256 patients have been enrolled at 19 sites using a 2:1 randomization with 162 patients assigned to CORTOSS and 94 patients assigned to PMMA. Dr. Hatten is one of the 19 clinical sites involved in the FDA Investigational Device Exemption (IDE) study and will cover part of a prospective randomized controlled study being conducted under an FDA IDE study. At the Indian River Radiology site, 57 patients have been enrolled; 36 treated using CORTOSS and 21 treated using PMMA bone cement."


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences